531 related articles for article (PubMed ID: 22107246)
1. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
Kebriaei P; Huls H; Jena B; Munsell M; Jackson R; Lee DA; Hackett PB; Rondon G; Shpall E; Champlin RE; Cooper LJ
Hum Gene Ther; 2012 May; 23(5):444-50. PubMed ID: 22107246
[TBL] [Abstract][Full Text] [Related]
2. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
[TBL] [Abstract][Full Text] [Related]
3. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
[TBL] [Abstract][Full Text] [Related]
4. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
[TBL] [Abstract][Full Text] [Related]
9. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
10. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
11. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
12. Sleeping beauty system to redirect T-cell specificity for human applications.
Maiti SN; Huls H; Singh H; Dawson M; Figliola M; Olivares S; Rao P; Zhao YJ; Multani A; Yang G; Zhang L; Crossland D; Ang S; Torikai H; Rabinovich B; Lee DA; Kebriaei P; Hackett P; Champlin RE; Cooper LJ
J Immunother; 2013 Feb; 36(2):112-23. PubMed ID: 23377665
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
14. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
[TBL] [Abstract][Full Text] [Related]
15. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
16. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
Brentjens RJ; Curran KJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():143-51. PubMed ID: 23233573
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
18. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
20. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
